Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 6Pancreatic Neoplasms 6Neoplasm Metastasis 6Colorectal Neoplasms 5Sarcoma, Ewing 4Ovarian Neoplasms 4Breast Neoplasms 4Neoplasms 3Insulin-Like Growth Factor I, Resistance To 3Carcinoma, Non-Small-Cell Lung 3Rectal Neoplasms 2Lymphoma 2Colonic Neoplasms 2Carcinoid Tumor 2Adenocarcinoma 2Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Recurrence 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Effusion, Malignant 1Pathologic Complete Response 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroectodermal Tumors, Primitive 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1

Interventions

ganitumab 1Vincristine 1Radiotherapy 1Ifosfamide 1Etoposide 1Doxorubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Askin Tumor × ganitumab × Clear all
NCT00563680 2016-10-27

QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors

NantCell, Inc.

Phase 2 Completed
38 enrolled
Sarcoma

Askin Tumor, Insulin-Like Growth Factor I, Resistance To, Sarcoma, Sarcoma, Ewing, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡